血管加压素联合肾上腺素与单用肾上腺素治疗院外心脏骤停的疗效:系统评价与Meta分析
该系统评价与Meta分析纳入截至2017年2月的随机对照试验,比较血管加压素联合肾上腺素(VE组)与单用肾上腺素(E组)治疗成人院外心脏骤停(OHCA),主要终点为自主循环恢复(ROSC)。共纳入9项研究、5047例OHCA患者,随机效应模型显示VE组ROSC率显著高于E组(OR=1.67,95%CI=1.13-2.49,P<0.00001,总I²=83%)。亚组分析显示,亚洲患者VE组ROSC改善显著(OR=3.30,95%CI=1.30-7.88),其他地区两组无差异(OR=1.07,95%CI=0.72-1.61)。结论认为血管加压素联合肾上腺素可改善亚洲OHCA患者的ROSC,其他地区患者未见获益。
要点
- 在OHCA成人中,血管加压素联合肾上腺素较单用肾上腺素提高ROSC率(OR=1.67,95%CI=1.13-2.49,P<0.00001),但异质性高(总I²=83%)。
- 亚洲OHCA患者亚组中,联合治疗与ROSC改善显著相关(OR=3.30,95%CI=1.30-7.88)。
- 其他地区OHCA患者亚组中,联合治疗与单用肾上腺素无差异(OR=1.07,95%CI=0.72-1.61)。
- 该Meta分析纳入9项RCT、5047例OHCA患者,主要终点为ROSC。
- 因地区亚组效应不同且异质性高,联合方案的效果可能受地域人群影响。
适用人群与场景
- 成人院外心脏骤停(OHCA)患者,纳入随机对照试验,比较血管加压素联合肾上腺素(VE组)与单用肾上腺素(E组)。
研究设计与关键结果
- 研究类型为系统评价与Meta分析,纳入截至2017年2月PubMed、EMBASE、Cochrane Library、万方数据库中比较血管加压素联合肾上腺素与单用肾上腺素的RCT,共9项研究、5047例OHCA患者。
- 主要终点ROSC:VE组高于E组,OR=1.67(95%CI=1.13-2.49,P<0.00001),总I²=83%。
- 亚组分析:亚洲患者VE组ROSC改善显著,OR=3.30(95%CI=1.30-7.88);其他地区患者两组无差异,OR=1.07(95%CI=0.72-1.61)。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析,纳入随机对照试验。
- 异质性:总I²=83%。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,根据亚组汇总结果,血管加压素联合肾上腺素可改善亚洲OHCA患者的ROSC,但其他地区OHCA患者不能从联合治疗中获益。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: The aim of this study was to conduct a meta-analysis to evaluate the efficacy of vasopressin-epinephrine compared to epinephrine alone in patients who suffered out-of-hospital cardiac arrest (OHCA).
METHODS: Relevant studies up to February 2017 were identified by searching in PubMed, EMBASE, the Cochrane Library, Wanfang for randomized controlled trials(RCTs) assigning adults with cardiac arrest to treatment with vasopressin-epinephrine (VEgroup) vs adrenaline (epinephrine) alone (E group). The outcome point was return of spontaneous circulation (ROSC) for patients suffering from OHCA. Heterogeneity, subgroup analysis, sensitivity analysis and publication bias were explored.
RESULTS: Individual patient data were obtained from 5047 participants who experienced OHCA in nine studies. Odds ratios (ORs) were calculated using a random-effects model and results suggested that vasopressin-epinephrine was associated with higher rate of ROSC (OR=1.67, 95% CI=1.13-2.49, P<0.00001, and total I2=83%). Subgroup showed that vasopressin-epinephrine has a significant association with improvements in ROSC for patients from Asia (OR=3.30, 95% CI=1.30-7.88); but for patients from other regions, there was no difference between vasopressin-epinephrine and epinephrine alone (OR=1.07, 95% CI=0.72-1.61).
CONCLUSION: According to the pooled results of the subgroup, combination of vasopressin and adrenaline can improve ROSC of OHCA from Asia, but patients from other regions who suffered from OHCA cannot benefit from combination of vasopressin and epinephrine.
参考来源
- Zhang Q, Liu B, Zhao L, et al. Efficacy of vasopressin-epinephrine compared to epinephrine alone for out of hospital cardiac arrest patients: A systematic review and meta-analysis. Am J Emerg Med. 2017. PMID: 28754320. doi:10.1016/j.ajem.2017.07.040
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。